Log in
NASDAQ:MDGL

Madrigal Pharmaceuticals Stock Forecast, Price & News

$121.07
-1.81 (-1.47 %)
(As of 09/21/2020 12:00 AM ET)
Add
Compare
Today's Range
$119.30
Now: $121.07
$121.63
50-Day Range
$100.18
MA: $107.23
$122.88
52-Week Range
$56.82
Now: $121.07
$127.25
Volume117,729 shs
Average Volume171,413 shs
Market Capitalization$1.87 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.16
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia. It is also developing MGL-3745, a THR-ß-selective small molecule that is in preclinical trials. The company has research, development, and commercialization agreement with Hoffmann-La Roche to develop, use, sell, offer for sale, and import various licensed products. Madrigal Pharmaceuticals, Inc. was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.
Read More
Madrigal Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.64 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:MDGL
CUSIP87162T20
Phone267-824-2827

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$27.00 per share

Profitability

Net Income$-83,950,000.00

Miscellaneous

Employees17
Market Cap$1.87 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$121.07
-1.81 (-1.47 %)
(As of 09/21/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MDGL News and Ratings via Email

Sign-up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Madrigal Pharmaceuticals (NASDAQ:MDGL) Frequently Asked Questions

How has Madrigal Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Madrigal Pharmaceuticals' stock was trading at $81.06 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MDGL stock has increased by 49.4% and is now trading at $121.07.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Madrigal Pharmaceuticals?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Madrigal Pharmaceuticals
.

When is Madrigal Pharmaceuticals' next earnings date?

Madrigal Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Madrigal Pharmaceuticals
.

How were Madrigal Pharmaceuticals' earnings last quarter?

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) announced its earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($3.18) earnings per share for the quarter, missing the Zacks' consensus estimate of ($2.43) by $0.75. During the same quarter last year, the business earned ($1.28) EPS.
View Madrigal Pharmaceuticals' earnings history
.

What price target have analysts set for MDGL?

12 brokers have issued 1 year price objectives for Madrigal Pharmaceuticals' stock. Their forecasts range from $114.00 to $208.00. On average, they anticipate Madrigal Pharmaceuticals' stock price to reach $168.40 in the next twelve months. This suggests a possible upside of 39.1% from the stock's current price.
View analysts' price targets for Madrigal Pharmaceuticals
.

Who are some of Madrigal Pharmaceuticals' key competitors?

What other stocks do shareholders of Madrigal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Exelixis (EXEL), Advaxis (ADXS), Viking Therapeutics (VKTX), Sangamo Therapeutics (SGMO), Amarin (AMRN), Crispr Therapeutics (CRSP), Intercept Pharmaceuticals (ICPT), Gilead Sciences (gild) and Sarepta Therapeutics (SRPT).

Who are Madrigal Pharmaceuticals' key executives?

Madrigal Pharmaceuticals' management team includes the following people:
  • Dr. Paul A. Friedman, Chairman & CEO (Age 76)
  • Dr. Rebecca A. Taub, Founder, Exec. VP of R&D, Chief Medical Officer and Director (Age 67)
  • Mr. Marc R. Schneebaum, Sr. VP & CFO (Age 65)
  • Mr. Thomas W. Hare, Sr. VP of Clinical Management

What is Madrigal Pharmaceuticals' stock symbol?

Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."

Who are Madrigal Pharmaceuticals' major shareholders?

Madrigal Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.30%), Jennison Associates LLC (1.15%), Goldman Sachs Group Inc. (0.68%), Candriam Luxembourg S.C.A. (0.66%), Frontier Capital Management Co. LLC (0.47%) and Charles Schwab Investment Management Inc. (0.40%). Company insiders that own Madrigal Pharmaceuticals stock include Bay City Capital Llc, Fred B Craves and Paul A Friedman.
View institutional ownership trends for Madrigal Pharmaceuticals
.

Which institutional investors are selling Madrigal Pharmaceuticals stock?

MDGL stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Jennison Associates LLC, Frontier Capital Management Co. LLC, Vanguard Group Inc., UBS Group AG, Alps Advisors Inc., Magnus Financial Group LLC, and Nuveen Asset Management LLC. Company insiders that have sold Madrigal Pharmaceuticals company stock in the last year include Bay City Capital Llc, and Fred B Craves.
View insider buying and selling activity for Madrigal Pharmaceuticals
.

Which institutional investors are buying Madrigal Pharmaceuticals stock?

MDGL stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Bank of America Corp DE, Two Sigma Advisers LP, Rafferty Asset Management LLC, WINTON GROUP Ltd, Swiss National Bank, Nisa Investment Advisors LLC, and Principal Financial Group Inc.. Company insiders that have bought Madrigal Pharmaceuticals stock in the last two years include Fred B Craves, and Paul A Friedman.
View insider buying and selling activity for Madrigal Pharmaceuticals
.

How do I buy shares of Madrigal Pharmaceuticals?

Shares of MDGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Madrigal Pharmaceuticals' stock price today?

One share of MDGL stock can currently be purchased for approximately $121.07.

How big of a company is Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals has a market capitalization of $1.87 billion. The biopharmaceutical company earns $-83,950,000.00 in net income (profit) each year or ($5.45) on an earnings per share basis. Madrigal Pharmaceuticals employs 17 workers across the globe.

What is Madrigal Pharmaceuticals' official website?

The official website for Madrigal Pharmaceuticals is www.madrigalpharma.com.

How can I contact Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The biopharmaceutical company can be reached via phone at 267-824-2827 or via email at [email protected]

This page was last updated on 9/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.